| Literature DB >> 32257810 |
Huan Chen1, Bijun Lian1, Zhenyang Dong1, Yan Wang1, Min Qu1, Feng Zhu1, Yinghao Sun1, Xu Gao1.
Abstract
OBJECTIVES: To summarize the experience of the first 500 robot-assisted laparoscopic radical prostatectomy (RALP) cases by one surgeon and analyze the influencing factors of functional and oncological outcomes.Entities:
Keywords: China; Learning curve; Prostate cancer; Prostatectomy; Robotic
Year: 2019 PMID: 32257810 PMCID: PMC7096692 DOI: 10.1016/j.ajur.2019.12.004
Source DB: PubMed Journal: Asian J Urol ISSN: 2214-3882
Preoperative characteristics for each group and overall.
| Clinical data | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Overall | |
|---|---|---|---|---|---|---|---|
| 1–100 | 101–200 | 201–300 | 301–400 | 401–500 | |||
| Age, mean±SD, year | 67.4±6.85 | 66.5±6.57 | 66.2±6.30 | 66.7±6.45 | 66.7±7.75 | 0.788 | 66.7 (6.79) |
| BMI, mean±SD, kg/m2 | 24.0±2.90 | 24.4±2.70 | 24.6±2.83 | 24.1±2.41 | 24.6±3.20 | 0.502 | 24.3 (2.82) |
| Preoperative PSA, | 0.342 | ||||||
| <4.0 | 4 (4.0) | 2 (2.0) | 1 (1.0) | 1 (1.0) | 2 (2.0) | 10 (2.0) | |
| 4.0–9.9 | 35 (35.0) | 34 (34.0) | 27 (27.0) | 32 (32.0) | 31 (31.0) | 159 (31.8) | |
| 10.0–19.9 | 31 (31.0) | 31 (31.0) | 33 (33.0) | 33 (33.0) | 32 (32.0) | 160 (32.0) | |
| >19.9 | 30 (30.0) | 33 (33.0) | 39 (39.0) | 34 (34.0) | 35 (35.0) | 171 (34.2) | |
| Clinical stage, | 0.005 | ||||||
| T1 | 30 (30) | 37 (37) | 63 (63) | 40 (40) | 24 (24) | 194 (38.8) | |
| T2 | 61 (61) | 54 (54) | 23 (23) | 41 (41) | 54 (54) | 23 (46.6) | |
| T2a | 31 (31.0) | 32 (32.0) | 12 (12.0) | 19 (19.0) | 13 (13.0) | 107 (21.4) | |
| T2b | 30 (30.0) | 21 (21.0) | 2 (2.0) | 6 (6.0) | 11 (11.0) | 70 (14.0) | |
| T2c | 0 (0.0) | 1 (1.0) | 9 (9.0) | 16 (16.0) | 30 (30.0) | 56 (11.2) | |
| T3 and T4 | 9 (9.0) | 9 (9.0) | 14 (14.0) | 19 (19.0) | 22 (22.0) | 73 (14.6) | |
| GS, | 0.633 | ||||||
| <7 | 21 (21.0) | 33 (33.0) | 30 (30.0) | 24 (24.0) | 21 (21.0) | 129 (25.8) | |
| =7 | 45 (45.0) | 38 (38.0) | 26 (26.0) | 35 (35.0) | 44 (44.0) | 188 (37.6) | |
| >7 | 34 (34.0) | 29 (29.0) | 44 (44.0) | 41 (41.0) | 35 (35.0) | 183 (36.6) | |
| D'Amico risk group, | 0.084 | ||||||
| Low | 12 (13.0) | 10 (10.0) | 14 (14.0) | 12 (12.0) | 10 (10.0) | 58 (11.8) | |
| Intermediate | 31 (33.0) | 38 (38.0) | 22 (22.0) | 26 (27.0) | 22 (22.0) | 139 (28.4) | |
| High | 57 (54.0) | 52 (52.0) | 64 (64.0) | 62 (61.0) | 68 (68.0) | 303 (59.8) |
BMI, body mass index; PSA, prostate-specific antigen; IQR, interquartile range; GS, Gleason score; SD, standard deviation.
Only one T4a case in group 1.
Comparison of age among five groups: ANOVA (analysis of variance).
Comparison of BMI between five groups: Kruskal–Wallis test.
Comparison of preoperative PSA, clinical stage, biopsy Gleason score, D'Amico risk group between five groups: Chi-square test.
Perioperative characteristics for each group and overall.
| Characteristics | Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Overall | |
|---|---|---|---|---|---|---|---|
| 1–100 | 101–200 | 201–300 | 301–400 | 401–500 | 500 | ||
| Operative time, median (IQR), min | 165 (140–198.75) | 130 (110–150) | 110 (100–123.75) | 105 (90–130) | 90 (75–105) | <0.001 | 120 (100–150) |
| Blood loss, median (IQR), mL | 200 (105–300) | 200 (100–200) | 100 (70–187.5) | 100 (100–200) | 100 (50–128.75) | <0.001 | 100 (100–200) |
| Postoperative hospital stays median (IQR), day | 9 (7–11) | 6 (5–8) | 5 (5–7) | 5 (4–7) | 5 (4–6) | 0.001 | 6 (5–8) |
| NVB preserving, | 1 | 1 | 6 | 26 | 34 | 68 | |
| Unilateral | 1 | 0 | 3 | 9 | 11 | ||
| Bilateral | 0 | 1 | 3 | 17 | 23 | ||
| T2 | 1 | 1 | 6 | 26 | 32 | ||
| T3 | 0 | 0 | 0 | 0 | 2 | ||
| Pathologic stage, | 0.001 | 500 | |||||
| pT2 | 75 (75) | 66 (66) | 47 (47) | 58 (58) | 54 (54) | 300 (60) | |
| pT3 | 23 (23) | 34 (34) | 53 (53) | 42 (42) | 45 (45) | 197 (39.4) | |
| pT4 | 2 (2) | 0 (0) | 0 (0) | 0 (0) | 1 (1) | 3 (0.6) | |
| Gleason score, | 0.201 | ||||||
| <7 | 20 (20) | 15 (15) | 13 (13) | 15 (15) | 14 (14) | 77 (15.4) | |
| =7 | 54 (54) | 64 (64) | 54 (54) | 58 (58) | 51 (51) | 281 (56.2) | |
| >7 | 26 (26) | 21 (21) | 33 (33) | 27 (27) | 35 (35) | 142 (28.4) | |
| PSM+ | 23 (23.5) | 24 (24.0) | 29 (29.0) | 18 (18.0) | 15 (15.2) | 0.143 | 109 (21.8) |
| pT2 | 13 (17.3) | 9 (13.6) | 5 (10.6) | 5 (8.6) | 4 (7.4) | 0.409 | 36 (12.0) |
| pT3 | 10 (43.5) | 15 (44.1) | 24 (45.3) | 13 (31.0) | 11 (24.4) | 0.170 | 73 (37.1) |
IQR, interquartile range; NVB, neurovascular bundle; PSM, positive surgical margin.
Comparison of operative time, blood loss, and postoperative hospital stays between five groups: Kruskal-Wallis test followed by stepwise step-down comparisons.
Comparison of pathologic stage, Gleason score, PSM between five groups: Chi-square test.
Figure 1The learning curve of intraoperative blood loss (A), operative time (B) and postoperative hospital stays (C).
Figure 2The continence recovery rate (A) and the biochemical recurrence-free survival rate (B). BCR, biochemical recurrence.
The association of possible risk factors of BCR.
| Covariate | Univariate analysis | Multivariate analysis | ||
|---|---|---|---|---|
| HR (95% CI) | HR (95% CI) | |||
| Postoperative GS | ||||
| =6 | 1 | 1 | ||
| >7 | 24.717 (5.827–100.272) | <0.0001 | 11.325 (2.590–49.520) | 0.0013 |
| Preoperative PSA | ||||
| <10 | 1 | 1 | ||
| >20 | 7.004 (3.672–13.359) | <0.0001 | 4.174 (2.077–8.391) | <0.0001 |
| Age | ||||
| ≤59 | 1 | |||
| 74 | 1.475 (0.638–3.411) | 0.3631 | ||
| BMI | ||||
| <24 | 1 | |||
| ≥24 | 1.100 (0.671–1.802) | 0.7065 | ||
| Pathologic T stage | ||||
| <T3a | 1 | 1 | ||
| ≥T3a | 5.802 (3.457–9.739) | <0.0001 | 2.344 (1.226–4.341) | 0.0067 |
| Pathologic N stage | ||||
| N0 | 1 | 1 | ||
| N1 | 6.366 (3.390–11.952) | <0.0001 | 1.756 (0.880–3.502) | 0.1102 |
| PSM | ||||
| Negative | 1 | |||
| Positive | 3.967 (2.410–6.528) | <0.0001 | 1.837 (1.052–3.207) | 0.0325 |
GS, Gleason score; PSA, prostate-specific antigen; BMI, body mass index; PSM, positive surgical margins; BCR, biochemical recurrence; HR, hazard rate; CI, confidence interal.
Reference group.